BioSpace News Archive

Business

empowerDX, a Subsidiary of Eurofins Scientific, and NIMA Partners Announce Strategic Partnership to Improve Celiac Disease Awareness and Support

Clinical Enterprise, Inc. d/b/a empowerDX, who offers the at-home Celiac Risk Gene Test, announced today that they have entered into an exclusive partnership with NIMA Partners, the makers of Gluten Sensor and Gluten Capsules for the detection of gluten in food particles.

September 14, 2022
·
3 min read
Policy

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

MediciNova, Inc. announced that it has received an Issue Notification from the U.S. Patent and Trademark Office for a new patent which covers MN-166 for the treatment of glioblastoma.

September 14, 2022
·
6 min read
Biotech Bay

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock - September 15, 2022

Akero Therapeutics, Inc. announced the pricing of an upsized underwritten public offering of 7,692,308 shares of its common stock at a public offering price of $26.00 per share.

September 14, 2022
·
5 min read
Business

Gemini BioProducts Announces Addition to Board of Directors

Gemini BioProducts Holding, Inc. (“GeminiBio” or the “Company”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a Florida-based healthcare private equity firm, announced the appointment of Cory Stevenson to its Board of Directors.

September 14, 2022
·
3 min read
BioMidwest

Independent Research Finds Underlying Method for C2N’s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer’s Diagnoses

A group of distinguished Alzheimer’s disease researchers has affirmed, in a new study published online in the journal Brain, the superiority of the methods that are the basis of C2N Diagnostics’ new p[hospho]-tau217 ratio test.

September 14, 2022
·
4 min read
Business

On Demand Pharmaceuticals and Wavelength Pharmaceuticals Awarded BIRD Foundation Grant

On Demand Pharmaceuticals, Inc. (ODP), and Wavelength Pharmaceuticals ( Petah Tikva , Israel ) - a SEQENS company, are pleased to announce that the US-Israel Binational Industrial Research & Development (BIRD) Foundation grant.

September 14, 2022
·
3 min read
Business

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the company’s significant pipeline of development candidates.

September 14, 2022
·
3 min read
Drug Development

Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced topline results from the Phase 2 clinical trial of ELX-02 in combination with ivacaftor in Class 1 cystic fibrosis (CF) patients with at least one nonsense mutation.

September 14, 2022
·
7 min read
BioCapital

Danaher CEO to Comment on Financial Performance - September 14, 2022

Danaher Corporation announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company’s third quarter 2022 performance in a presentation at its investor and analyst event.

September 14, 2022
·
8 min read
Genetown

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Nantucket Therapeutics Conference.

September 14, 2022
·
1 min read